Summary by Futu AI
Bristol-Myers Squibb Company (BMY.US), a leading pharmaceutical company, has filed its annual Form 11-K report with the Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report, signed on June 25, 2024, by Senior Vice President and Treasurer Sandra Ramos-Alves, includes comprehensive financial statements for the Bristol-Myers Squibb Company Savings and Investment Program. The audited financial statements reveal that the net assets available for benefits increased significantly from $8,960,971 in 2022 to $10,303,645 in 2023. The report also details the Program's investment in participant-directed investments, employer contributions, and participant loans. The Program, which is a defined contribution retirement plan, includes a variety of investment options and is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA). The independent audit, conducted by Withum Smith + Brown, PC, concluded that the financial statements present fairly the net assets and changes in net assets for the year in conformity with U.S. generally accepted accounting principles.